Meningioma: A Review of Clinicopathological and Molecular Aspects
Meningiomas are the most the common primary brain tumors in adults, representing approximately a third of all intracranial neoplasms. They classically are found to be more common in females, with the exception of higher grades that have a predilection for males, and patients of older age. Meningioma...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2020.579599/full |
| _version_ | 1818242189110542336 |
|---|---|
| author | Kristin Huntoon Angus Martin Shaw Toland Sonika Dahiya |
| author_facet | Kristin Huntoon Angus Martin Shaw Toland Sonika Dahiya |
| author_sort | Kristin Huntoon |
| collection | DOAJ |
| description | Meningiomas are the most the common primary brain tumors in adults, representing approximately a third of all intracranial neoplasms. They classically are found to be more common in females, with the exception of higher grades that have a predilection for males, and patients of older age. Meningiomas can also be seen as a spectrum of inherited syndromes such as neurofibromatosis 2 as well as ionizing radiation. In general, the 5-year survival for a WHO grade I meningioma exceeds 80%; however, survival is greatly reduced in anaplastic meningiomas. The standard of care for meningiomas in a surgically-accessible location is gross total resection. Radiation therapy is generally saved for atypical, anaplastic, recurrent, and surgically inaccessible benign meningiomas with a total dose of ~60 Gy. However, the method of radiation, regimen and timing is still evolving and is an area of active research with ongoing clinical trials. While there are currently no good adjuvant chemotherapeutic agents available, recent advances in the genomic and epigenomic landscape of meningiomas are being explored for potential targeted therapy. |
| first_indexed | 2024-12-12T13:41:16Z |
| format | Article |
| id | doaj.art-634e809a466f4d898fdc068769c52021 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-12T13:41:16Z |
| publishDate | 2020-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-634e809a466f4d898fdc068769c520212022-12-22T00:22:48ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-10-011010.3389/fonc.2020.579599579599Meningioma: A Review of Clinicopathological and Molecular AspectsKristin Huntoon0Angus Martin Shaw Toland1Sonika Dahiya2Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, United StatesDepartment of Pathology, Stanford University, Stanford, CA, United StatesDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, United StatesMeningiomas are the most the common primary brain tumors in adults, representing approximately a third of all intracranial neoplasms. They classically are found to be more common in females, with the exception of higher grades that have a predilection for males, and patients of older age. Meningiomas can also be seen as a spectrum of inherited syndromes such as neurofibromatosis 2 as well as ionizing radiation. In general, the 5-year survival for a WHO grade I meningioma exceeds 80%; however, survival is greatly reduced in anaplastic meningiomas. The standard of care for meningiomas in a surgically-accessible location is gross total resection. Radiation therapy is generally saved for atypical, anaplastic, recurrent, and surgically inaccessible benign meningiomas with a total dose of ~60 Gy. However, the method of radiation, regimen and timing is still evolving and is an area of active research with ongoing clinical trials. While there are currently no good adjuvant chemotherapeutic agents available, recent advances in the genomic and epigenomic landscape of meningiomas are being explored for potential targeted therapy.https://www.frontiersin.org/articles/10.3389/fonc.2020.579599/fullmeningiomatargeted treatmentmolecular diagnosisimmunotherapyneurosurgeryclinical trials |
| spellingShingle | Kristin Huntoon Angus Martin Shaw Toland Sonika Dahiya Meningioma: A Review of Clinicopathological and Molecular Aspects Frontiers in Oncology meningioma targeted treatment molecular diagnosis immunotherapy neurosurgery clinical trials |
| title | Meningioma: A Review of Clinicopathological and Molecular Aspects |
| title_full | Meningioma: A Review of Clinicopathological and Molecular Aspects |
| title_fullStr | Meningioma: A Review of Clinicopathological and Molecular Aspects |
| title_full_unstemmed | Meningioma: A Review of Clinicopathological and Molecular Aspects |
| title_short | Meningioma: A Review of Clinicopathological and Molecular Aspects |
| title_sort | meningioma a review of clinicopathological and molecular aspects |
| topic | meningioma targeted treatment molecular diagnosis immunotherapy neurosurgery clinical trials |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2020.579599/full |
| work_keys_str_mv | AT kristinhuntoon meningiomaareviewofclinicopathologicalandmolecularaspects AT angusmartinshawtoland meningiomaareviewofclinicopathologicalandmolecularaspects AT sonikadahiya meningiomaareviewofclinicopathologicalandmolecularaspects |